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Abstract 
CCCTC-binding factor (CTCF), a ubiquitous 11-zinc finger multifunctional protein, has distinct 
molecular functions, such as transcriptional activation, repression, and chromatin barrier activity, 
in a locus-specific manner. Elevated CTCF levels in breast cancer cells are known to contribute to 
tumorigenesis; however, the underlying mechanism remains elusive. We investigated the effect of 
CTCF expression on breast cancer cell survival and elucidated its mechanism. CTCF depletion in 
MCF-7 cells led to a decreased cell growth and proliferation, surpassing the growth of normal cells 
under co-culture system of MCF-7-GFP and MCF10A. Here we propose that the phenotypes 
observed in CTCF-depleted MCF-7 cancer cells, such as reduced cell proliferation, increased 
apoptosis, and cell cycle arrest, are closely linked with the activation of p53. The consensus 
CTCF-binding site, located approximately 800 bp upstream of the first exon of TP53, was marked 
by H3K27me3, but not by the active mark H3K4me3, although CTCF is expressed. Knockdown of 
CTCF conversely led to the recruitment of H3K4me3 instead of H3K27me3, accompanying with 
the higher enrichment of PolII in the proximal promoter region of TP53. With the activation of p53, 
increased p21 and Bax expressions were observed in CTCF knockdown MCF-7 cells. Elucidating 
functional roles of CTCF and regulation mechanisms may help to guide CTCF and/or its related 
molecules as a therapeutic target to prevent cancer cell growth. 
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Introduction 
CCCTC-binding factor (CTCF) is a widely 
expressed 11-zinc finger multifunctional protein that 
is involved in different aspects of gene regulation 
including promoter activation or repression, 
chromatin insulation, and genomic imprinting [1]. 
The suggestive role of CTCF in cancer tumorigenesis 
was from the discovery of CTCF as a transcriptional 
repressor of the chicken c-myc gene [2, 3], and the 
subsequent identification of the regulatory role of the 
mammalian c-myc oncogene [4]. Elucidation of CTCF 
functions in the regulation of a wide range of genes 
involved in apoptosis, growth, proliferation, and 
differentiation has further aroused the interest in the 
involvement of CTCF in tumorigenesis [5-7]. Based on 
the current knowledge of CTCF somatic mutations in 
different cancers as well as the growth inhibitory 
effect of CTCF in cancer cells and xenograft models, 
CTCF has been postulated as a candidate tumor 
suppressor gene [8-10]. Through powerful genomic 
platforms and sequence data integration [11, 12], 
CTCF has recently been identified as one of the genes 
that harbor driver mutations in breast cancer. 
Paradoxically, however, CTCF levels were found to be 
elevated rather than reduced in many breast cancer 
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cell lines as well as in breast tumors [13]. 
Overexpression of CTCF has been thought to confer a 
selective survival advantage to cancer cells by 
protecting these cells from apoptosis through the 
epigenetic regulation of Bax expression [13, 14]. 
Nevertheless, the exact mechanism of CTCF and 
involved factors still need to be elucidated.  
Here, we investigated the effect of CTCF on 
breast cancer cell survival and elucidated its 
mechanism in MCF-7 cells. In addition, as a 
convenient way to compare the CTCF knockdown 
effect between breast cancer cells and normal cells, a 
co-culture system was established by generating 
GFP-expressing MCF-7 cells and co-culturing them 
with normal epithelial MCF10A cells. We showed that 
CTCF depletion had a differential effect on breast 
cancer cell and normal cell growth. The decreased cell 
proliferation and increased apoptosis observed in 
CTCF knockdown breast cancer cells were correlated 
with the activation of p53 and its downstream 
signaling.  
Methods  
Cell lines and cell culture 
Breast cancer cell lines MCF-7 and normal breast 
epithelial cell line MCF10A were cultured as 
described previously [15]. In order to distinguish 
cancer cells (MCF-7) from normal cells (MCF10A) in a 
co-culture system, GFP-expressing stable MCF-7 cell 
lines were generated by transfection of the GFP 
expression vector pEGFP-N1 (Clontech, Mountain 
View, CA, USA) using Lipofectamine 2000TM 
(Invitrogen, Carlsbad, CA, USA) and selection with 
G418. CTCF mRNA expression levels were analyzed 
for three homogenous stable cell lines 
(MCF-7-GFP-H1, -H2, and -H3) as well as a hetero 
pool. The MCF-7-GFP-H3 cell line was used for 
co-culture with MCF10A.  
Overexpression and knockdown of CTCF 
Full length CTCF cDNA was cloned into the 
pcDNA3 vector (pcDNA3-CTCF). Breast cancer cell 
lines were transfected with either control pcDNA3 or 
pcDNA3-CTCF using Attractene (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. 
For CTCF depletion, shRNA oligonucleotides 
targeting two different positions on CTCF mRNA 
(shCTCF-1; 5’-GCGGAAAGTGAACCCATGATA-3’, 
shCTCF-2; 5’-CCTCCTGAGGAATCACCTTAA-3’) 
were designed, synthesized (Cosmo Genetech, Seoul, 
Korea), and cloned into the pLKO.1-puro vector. 
Packaging plasmid (pCMV-dR8.91) and envelop 
plasmid (pVSV-G) were co-transfected with control 
(pLKO.1), NS shRNA containing vector (pLKO1-NS), 
or shCTCF containing vector (pLKO1-shCTCF1 or 
pLKO1-shCTCF2) using Lipofectamine 2000TM 
(Invitrogen) in HEK-293T cells. MCF-7 cells were 
transduced with lentiviral particles. Selection was 
performed using puromycin (1.5 µg/mL), and CTCF 
knockdown was confirmed by RT-PCR. The 
experimental timeline for CTCF knockdown cells is 
presented in Figure S1.  
Cell proliferation, cell cycle analysis and 
apoptosis 
Cell proliferation was measured by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. For cell cycle analysis, MCF-7 
cells were harvested and fixed in ice-cold 70% 
ethanol. The fixed cells were collected by 
centrifugation, stained with a mixture 
of RNase and PI for 45 min at 37 °C, and analyzed by 
fluorescence-activated cell sorter (FACS). The EzWay 
Annexin V-FITC Apoptosis Detection Kit (Koma 
Biotech, Seoul, Korea) was used to detect apoptosis.  
RNA isolation and RT-PCR 
Total RNA was isolated from the cultured cells 
using TRIzol reagent (Invitrogen) according to the 
manufacturer’s instruction. cDNA was generated 
using ImProm-IITM Reverse Transcriptase (Promega, 
Madison, WI, USA). PCR was performed in replicates 
using G Taq polymerase (Cosmo Genentech, Seoul, 
Korea). The PCR primers used in this study are listed 
in Table S1. ImageJ software was used for 
quantification.  
Dual luciferase assay  
Genomic DNA fragments from the TP53 locus 
were amplified using pfu polymerase (Solgent, 
Daejeon, Korea) and cloned into the pGL3-basic 
vector (Promega) using KpnI and HindIII sites to 
generate pGL3-TP53. Restriction enzyme sites were 
incorporated via forward and reverse primers (Table 
S1). MCF-7 cells were co-transfected with the Renilla 
luciferase vector (pRL Renilla luciferase control) and 
either the control pGL3-basic vector or the pGL3-TP53 
construct using Attractene (Qiagen) according to the 
manufacturer’s protocol. Promoter activity was 
measured using the Dual-Luciferase Reporter Assay 
System (Promega) after 72 h of transfection and 
normalized using the Renilla luciferase signal. To 
analyze the effect of CTCF on promoter activity, 
MCF-7 cells were co-transfected with the Renilla 
luciferase vector and pGL3-TP53 vector with either 
control pcDNA3 or pcDNA3-CTCF, and promoter 
activities were measured as previously described. A 
minimum of four independent biological replicates 
were examined to obtain reliable results.  
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Chromatin immunoprecipitation (ChIP) 
analysis 
Chromatin was prepared from MCF-7 cells by 
fixing the cells in 37% formaldehyde for 15 min, 
followed by quenching with glycine (2.5 M) for 10 
min. Sonication of cross-linked genomic DNA was 
performed using Sonics Vibra CellTM to obtain 
500~1,000 bp DNA fragments. ChIP was performed 
using antibodies against CTCF (#3418; Cell Signaling), 
PolII (sc-56767; Santa Cruz Biotechnology, CA, USA), 
H3K4me3 (#1012; Abcam, Cambridge, UK), 
H3K27me3 (ab6002; Abcam), and IgG (Santa Cruz, 
sc-2027). Immunoprecipitated DNA was purified and 
used for PCR. The primers amplifying site A and B 
(Figure 3A) are shown in the Table S1. A minimum of 
three independent biological replicates were used for 
quantitation. 
Immunocytochemistry  
Cells grown on coverslips were fixed in 4% PFA. 
Antibodies against CTCF, p53 (sc-126; Santa Cruz,), 
ITGB4 (ab133682; Abcam) and the corresponding 
secondary antibodies (anti-rabbit IgG Alexa Flour 594 
and anti-goat IgG Alexa Flour 488; Invitrogen) were 
used for detection. Cells were counter stained with 
DAPI (Invitrogen) and analyzed using a Zeiss 
LSM700 confocal microscope. 
Autophagy detection by Lysotracker 
Lysotracker DND-26 (#8783, Cell Signaling 
Technology, Inc., Danvers, MA, USA) was diluted 
1:10000 directly into cell culture media to make 100 
nM final concentration. Live cells were stained with 
LysoTracker Green DND-26 and Hoechst 34580 for 
lysosomes and nucleus, respectively, and were 
analyzed using fluorescent microscopy immediately 
after treatment without fixation. 
Statistical analysis 
For all the experiments, a minimum of three 
independent biological replicates were analyzed for 
quantitation. Data are expressed as the mean value 
with standard error. Statistical differences were 
determined by Student’s t-test. A p value of < 0.05 
was considered statistically significant. 
Results  
Depletion of CTCF negatively affects the 
survival of breast cancer cells 
CTCF is ubiquitously expressed, however, its 
expression levels are variable in different breast 
cancer cell lines [13]. As CTCF is known to contribute 
to cancer cell survival through regulation of the 
proapoptotic gene Bax [13, 14], we first examined the 
effect of CTCF depletion on cellular processes such as 
cell proliferation, cell cycle distribution, and 
apoptosis. shRNA-mediated CTCF knockdown with 
two different target sequences (KD1 and KD2) 
successfully reduced CTCF expression level with 
similar efficiency (Figure 1A). A time course 
experiment with CTCF knockdown showed that 
MCF-7 cell proliferation was gradually decreased 
over a period of time (Figure 1B). Cell cycle analysis 
using FACS on day 2 after infection with lentivirus 
containing shRNA against CTCF or non-specific (NS) 
shRNA revealed that CTCF-depleted MCF-7 cells 
showed the increased G1 and decreased S phase 
populations compared with those of control cells 
(Figure 1C). In addition, an increased number of 
apoptotic cells were observed in CTCF-depleted cells 
by Annexin V and PI staining (Figure 1D).  
Since CTCF knockdown in normal MCF10A 
breast epithelial cells did not affect cell proliferation 
rate in a same time period (Figure S2), we supposed a 
higher dependency of cancer cells than normal breast 
epithelial cells on CTCF for survival. In order to 
confirm the negative effects of CTCF depletion on the 
survival of breast cancer cells, we developed a 
co-culture system in which green GFP-expressing 
MCF-7 cancer cells and normal MCF10A cells grew 
together (MCF-7-GFP and MCF10A, Figure S3) and 
observed the effect of CTCF knockdown on the two 
cell types. Control MCF-7-GFP and MCF10A cells 
infected with NS shRNA viral particles aggregated to 
form individual cell colonies with identical cells after 
day 4; thus, we were able to distinguish bright green 
MCF-7-GFP colonies from non-green MCF10A 
colonies (Figure 2A, upper row, and 2B). However, 
MCF-7-GFP cells failed to maintain their colonies 
when CTCF was depleted, which led to the 
overwhelming growth of normal MCF10A cells on the 
remaining empty surface (Figure 2A, lower row, and 
2C). Possibly for the same reason, we were not able to 
obtain stable cell lines that express CTCF shRNA 
(data not shown). These observations confirm that 
long-term depletion of CTCF negatively affects cancer 
cell (not normal cell) survival and colony formation.  
CTCF directly binds to the upstream region of 
TP53 and negatively regulates its expression 
through epigenetic modification 
The consistent results achieved suggest that 
CTCF depletion activates the p53 signaling cascade 
and induces breast cancer cell death via apoptosis and 
cell cycle arrest. To determine whether the effects of 
CTCF on cancer cell survival are through the p53 
pathway, we examined the mRNA levels of p53 and 
its downstream cascade members, p21 and Bax. 
Following CTCF knockdown, p53, p21, and Bax were 
upregulated (Figure 3A). By using data from 
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ENCODE, we loaded the CTCF ChIP-seq data from 
MCF-7 (GSM822305) into a track in the UCSC genome 
browser and identified a high enrichment of CTCF on 
the promoter region approximately 800 bp upstream 
of the TP53 transcription start site where a consensus 
CTCF-binding site (CBS) was detected (Figure 3B, 
Figure S4). The second highest peak in the proximal 
upstream region of the first exon did not contain a 
CBS. ChIP assay with CTCF antibody demonstrated 
that CTCF was predominantly bound to the 
CBS-containing site A rather than site B (Figure 3C, 
upper panel). The enrichment of CTCF on site A was 
reduced in CTCF knockdown cells (CTCF-KD). On 
the other hand, site B was bound with RNA 
polymerase II (PolII) and its enrichment was higher 
when CTCF was depleted (Figure 3C, lower panel). 
Therefore, we suggest that CTCF directly binds to the 
upstream region of TP53 (site A) and negatively 
regulates its expression, probably by preventing the 
binding of PolII with the TSS site. ChIP experiments 
with histone antibodies showed that the repressive 
mark H3K27me3 was enriched in control cells 
whereas the active mark H3K4me3 was enriched in 
CTCF-depleted cells (Figure 3D), which were 
consistent with p53 expression status. Luciferase 
reporter analysis demonstrated the promoter activity 
of a genomic fragment (-810 to +188 bp) of the TP53 
locus, which gradually decreased as the amount of 
CTCF increased (Figure 3E and F). 
Immunocytochemistry analysis with CTCF and p53 
clearly showed reduction of CTCF and increased p53 
expression in CTCF knockdown cells (Figure 4).  
CTCF influences autophagy in MCF-7 cells 
To analyze the effect of CTCF on autophagy, 
mRNA levels of two important autophagy markers 
p62 (SQSTM1) and ATG13 were measured in control 
and CTCF-overexpressing (pCTCF) MCF-7 cells. 
When CTCF was overexpressed, the expression levels 
of p62 and ATG13 were increased (Figure 5A) 
implying that the autophagy is activated by CTCF. 
Inversely, when CTCF was knockdown, reduced 
intensities in Lysotracker staining (see Materials and 
Methosd) was detected (Figure 5B), suggesting the 
reduced activity of lysosomes upon the reduction of 
CTCF in MCF-7 cells.  
 
Figure 1. Effect of CTCF knockdown on cell proliferation, cell cycle and apoptosis in MCF-7 cells. (A) mRNA expression of CTCF in CTCF knockdown (KD1 and KD2) and 
control (non-specific [NS] and empty vector [pLKO]) cells. (B) Cell proliferation was monitored by MTT assay in a time course experiment of MCF-7 cells for the CTCF 
knockdown (KD1 and KD2) and control (non-specific [NS] and empty vector [pLKO]) group. Y-axis represents the mean value with standard error of the relative 
proliferation rate. (C) FACS analysis of cell cycle by PI staining. Cell cycle distribution of control non-specific (Control-NS) and CTCF knockdown (CTCF-KD) MCF-7 cells. The 
distributions of cell populations in each cell cycle phase are presented as bar graphs (lower panel). Data are expressed as the mean value with standard error. (D) FACS analysis 
of apoptosis by Annexin V and PI staining for Control-NS and CTCF-KD MCF-7 cells as well as parent MCF-7 cells. The ‘% of apoptotic cells’ shown in a bar graph is the sum of 
‘early apoptotic’ (bottom right) and ‘apoptotic’ (top right) cell population in the scatter plot. Data are expressed as the mean value with standard error from three 
experimental replicates. 
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Figure 2. Growth of co-cultured MCF-7 and MCF10A cells under CTCF-depleted conditions. Fluorescence microscopy of MCF-7-GFP and MCF10A cells for the control-NS 
and CTCF-KD group. Cell growth was monitored at day 1, 2, 3, 4, and 6. (B-C) Zoomed-in images of the square boxes shown in (A).  
 
Figure 3. Negative regulation of CTCF on p53 expression. (A) mRNA expression of CTCF, p53, p21, and Bax in CTCF knockdown (KD1 and KD2) and control (non-specific 
[NS] and empty vector [pLKO]) cells. (B) Schematic view of the TP53 gene locus with a CTCF-binding site (CBS). ‘A’ and ‘B’ represent amplified regions for ChIP-PCR. See Figure 
S4 for details. (C) ChIP-PCR analysis for CTCF and PolII binding on site A and B in Control-NS and CTCF-KD MCF-7 cells. (D) ChIP-PCR results for H3K4me3 and H3K27me3 
on site A in Control-NS and CTCF-KD cells. (E-F) Analysis of TP53 promoter activity by the luciferase reported plasmid pGL3-TP53 (E) and CTCF dose-dependent inhibition of 
TP53 promoter activity in MCF-7 cells (F). Data are expressed as the mean value with standard error from four experimental replicates. The TP53 genomic region cloned into 
the pGL3 vector is presented in (B). 
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Figure 4. CTCF and p53 protein expression in MCF-7 cells. Fluorescence microscopy images show the expression of p53 (green) and CTCF (red) in control non-specific 
(Control-NS; A-D) and CTCF knockdown (CTCF-KD; E-H) cells. D and H are merged images of the green, red, and DAPI (blue) channel. Scale bar: 200 µm.  
 
Figure 5. Analysis of autophagy. (A) mRNA levels of autophagy markers, p62 and ATG13, in control (empty vec), CTCF overexpressing (CTCF), and untreated MCF-7 cells. (B) 
Fluorescent microscopy images of MCF-7 control non-specific (Control-NS) and CTCF-knockdown (CTCF-KD) cells stained with LysoTracker Green DND-26 and Hoechst 
34580 for lysosomes and nucleus, respectively. 
 
Discussion  
In this study, we provided experimental 
evidence to demonstrate the contribution of CTCF to 
the survival of MCF-7 breast cancer cells. CTCF acts as 
a transcriptional repressor of p53 by binding to its 
upstream region and creating a local chromatin 
environment generally associated with transcriptional 
suppression. Here, we demonstrated that depletion of 
CTCF in breast cancer cells induced p53 and its 
downstream genes, such as p21 and Bax, leading to 
cell cycle arrest and apoptosis. The effect of CTCF 
inhibition on breast cancer cell growth does not seem 
to be limited to MCF-7 cells, since knockdown of 
CTCF in other ER-positive cell line, T47D, also 
resulted in the reduction of cell proliferation (Figure 
S5).   
A previous study demonstrating the epigenetic 
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regulation of p53 by CTCF in other transformed cell 
lines [16] suggested that CTCF assists in maintaining 
an open configuration of chromatin for p53 
transcriptional expression, thus supporting a tumor 
suppressive role of CTCF. However, the contradictory 
phenomena observed in the breast cancer cells, that is, 
high upregulation of CTCF and the resulting survival 
advantages conferred to breast cancer cells 
[13] cannot be simply explained by tumor suppressive 
role of CTCF and its positive function for p53. 
Recently, Méndez-Catalá et al. reported that 
knockdown of CTCF led to apoptosis in breast cancer 
cells and demonstrated the preferential binding of 
CTCF to the Bax promoter in breast cancer cells by 
comparison with non-breast cells [14]. However, their 
results were not associated with CTCF action on p53 
and its downstream effect. Our data provide evidence 
for a direct link between CTCF and p53 in mediating 
cancer cell survival. Unlike previous observations in 
other cancer cell types [16], CTCF was predominantly 
bound in the approximately 800 bp upstream region 
of TP53 containing a CBS rather than in the proximal 
promoter region in MCF-7 breast cancer cells. CTCF 
bound to the TP53 upstream region was released by 
CTCF depletion, accompanying the enrichment of 
H3K4me3 instead of H3K27me3. ChIP-seq data 
deposited in ENCODE are consistent with our data 
showing a negative correlation between CTCF and 
H3K4me3 enrichment on the marked CBS (Figure S4). 
Therefore, depletion of CTCF could play an important 
role in releasing the p53 gene from 
its transcriptionally silenced status. The resulting 
expression of p53 and activation of its signaling 
cascade would support its tumor suppressive role in 
inducing cell cycle arrest and apoptosis. Activation of 
the p53 pathway was demonstrated by monitoring 
the transcriptional expression levels of p53 
downstream genes, such as p21 and Bax, and by 
examining cellular physiological states. In addition, 
the decreased cytoplasmic expression of integrin-beta 
4 (ITGB4), a known p53 target, was found to be 
associated with p53 expression in the nucleus of 
CTCF-depleted MCF-7 cells (Figure S6). The loss of 
ITGB4 expression and the subsequent disruption 
of ITGB4-mediated cell adhesion may contribute to 
apoptotic cell death and growth arrest.  
Autophagy and apoptosis are two important 
cellular processes that maintain organismal and 
cellular homeostasis. The interplay between these two 
processes is quite complicated and thus difficult to 
generalize; nevertheless, autophagy generally 
blocks the induction of apoptosis [17]. Our results 
showing CTCF-induced autophagy suggest that high 
CTCF expression facilitates the progression of breast 
cancer cells by activating autophagy but also by 
blocking apoptosis; conversely, knockdown of CTCF 
suppresses autophagy and induces apoptosis by 
activating the p53 pathway.  
 Collectively, we demonstrated that CTCF 
induces the transcriptional silencing of p53, 
contributing to breast cancer cell survival and 
tumorigenesis. These results are noteworthy because 
they suggest a new method to limit the growth and 
spread of breast cancer cells by selectively promoting 
apoptotic cell death via inhibition of CTCF 
expression. 
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